Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients.

Hanke N, Kunz C, Thiemann M, Fricke H, Lehr T.

Pharmaceutics. 2019 Apr 1;11(4). pii: E152. doi: 10.3390/pharmaceutics11040152.

2.

Freeze-Drying From Organic Co-Solvent Systems, Part 2: Process Modifications to Reduce Residual Solvent Levels and Improve Product Quality Attributes.

Kunz C, Schuldt-Lieb S, Gieseler H.

J Pharm Sci. 2019 Jan;108(1):399-415. doi: 10.1016/j.xphs.2018.07.002. Epub 2018 Jul 12.

PMID:
30017885
3.

Merits and Limitations of Dynamic Vapor Sorption Studies on the Morphology and Physicochemical State of Freeze-Dried Products.

Kunz C, Gieseler H.

J Pharm Sci. 2018 Aug;107(8):2179-2191. doi: 10.1016/j.xphs.2018.04.016. Epub 2018 Apr 24.

PMID:
29698727
4.

Factors Influencing the Retention of Organic Solvents in Products Freeze-Dried From Co-Solvent Systems.

Kunz C, Gieseler H.

J Pharm Sci. 2018 Aug;107(8):2005-2012. doi: 10.1016/j.xphs.2018.04.001. Epub 2018 Apr 9. Review.

PMID:
29649470
5.

Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.

Boch T, Luft T, Metzgeroth G, Mossner M, Jann JC, Nowak D, Meir F, Schumann C, Klemmer J, Brendel S, Fricke H, Kunz C, Weiß C, Hofmann WK, Nolte F.

Leuk Res. 2018 May;68:62-69. doi: 10.1016/j.leukres.2018.03.007. Epub 2018 Mar 10.

PMID:
29549809
6.

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.

Blaes J, Thomé CM, Pfenning PN, Rübmann P, Sahm F, Wick A, Bunse T, Schmenger T, Sykora J, von Deimling A, Wiestler B, Merz C, Jugold M, Haberkorn U, Abdollahi A, Debus J, Gieffers C, Kunz C, Bendszus M, Kluge M, Platten M, Fricke H, Wick W, Lemke D.

Mol Cancer Res. 2018 May;16(5):767-776. doi: 10.1158/1541-7786.MCR-17-0563. Epub 2018 Feb 16.

7.

Freeze-Drying From Organic Cosolvent Systems, Part 1: Thermal Analysis of Cosolvent-Based Placebo Formulations in the Frozen State.

Kunz C, Schuldt-Lieb S, Gieseler H.

J Pharm Sci. 2018 Mar;107(3):887-896. doi: 10.1016/j.xphs.2017.11.003. Epub 2017 Nov 10.

PMID:
29133233
8.

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.

Raimbault A, Pierre-Eugene C, Rouquette A, Deudon C, Willems L, Chapuis N, Mathis S, Kunz C, Fricke H, Kosmider O, Bardet V, Fontenay M; Groupe Francophone des Myélodysplasies.

Oncotarget. 2016 Mar 22;7(12):14898-911. doi: 10.18632/oncotarget.7469.

9.

A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.

Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, Wiestler B, Schliesser MG, von Deimling A, Pichler J, Vetlova E, Harting I, Debus J, Hartmann C, Kunz C, Platten M, Bendszus M, Combs SE.

Clin Cancer Res. 2014 Dec 15;20(24):6304-13. doi: 10.1158/1078-0432.CCR-14-0951-T. Epub 2014 Oct 22.

10.

Influence of lithium cations on prolyl peptide bonds.

Kunz C, Jahreis G, Günther R, Berger S, Fischer G, Hofmann HJ.

J Pept Sci. 2012 Jun;18(6):400-4. doi: 10.1002/psc.2410. Epub 2012 Apr 20.

PMID:
22522384
11.

Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients.

Tuettenberg J, Seiz M, Debatin KM, Hollburg W, von Staden M, Thiemann M, Hareng B, Fricke H, Kunz C.

Int Immunopharmacol. 2012 May;13(1):93-100. doi: 10.1016/j.intimp.2012.03.004. Epub 2012 Mar 21.

PMID:
22446296
12.

Supplemental Content

Loading ...
Support Center